Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer/Coley lung cancer agent starts Phase III

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Coley and partner Pfizer have initiated a Phase III program evaluating the toll-like receptor agonist PF-3512676 (formerly ProMune) for first-line treatment of advanced non-small cell lung cancer, Coley says Nov. 28. Two 800-patient studies are being conducted under an FDA special protocol assessment and will evaluate the drug in combination with current standard-of-care chemo regimens; the primary endpoint is overall survival. Pfizer and Coley entered into a development and commercialization agreement for PF-3512676 in March (Pharmaceutical Approvals Monthly April 2005, p. 26)...

You may also be interested in...

Licensing In Brief

Pfizer to fund Phase III ProMune trials for lung cancer under licensing pact valued at up to $505 mil., plus royalties. Medicis gains Botox competitor in $2.8 bil. Inamed purchase. Baxter gets U.S. rights to Cangene WinRho SDF for bleeding disorder. More licensing deals in brief

Finance Watch: Two SPAC Deals, Two IPOs Take Four Biopharmas Public

Public Company Edition: Mergers with special purpose acquisition corporations may be heating up, but in addition to the Surrozen and Tango SPAC deals Recursion and Biomea launched initial public offerings. Also, Organon sells $5.6bn worth of notes to fund spinout from Merck & Co.

#ClinicalTrialsSoWhite: How Drug Makers Are Using COVID-19 To Improve Trial Diversity

Efforts to improve trial diversity predate COVID-19, but the pandemic’s disproportionate effects on minority communities have brought the issue to the forefront.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts